Back to Market Feed

Product Information

TREMFYA 200 MG/2 ML PEN is a brand product labeled by Janssen Biotech, Inc., priced at $7318.9883 per ML under NDC 57894065102. Its NADAC has been published 36 times since Dec 17, 2025.

TREMFYA 200 MG/2 ML PEN

guselkumab
$7318.9883per ML

Strength

200 mg/2mL

NDC

57894065102

Classification

Brand

Dosage Form

INJECTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

GUSELKUMAB

Approval Type

Biologic (BLA)

FDA Application

BLA761061

On Market Since

9/11/2024

Pharmacological Classes

Interleukin-23 Antagonist
Interleukin-23 Antagonists

Price Statistics

The NADAC for TREMFYA 200 MG/2 ML PEN has been published 36 times since Dec 17, 2025, and over the history we have for it it has risen 4.6%. The table below summarizes its recorded NADAC range and movement.

Current price$7318.9883 per ML
All-time high$7349.6703 (Jul 15, 2026)
All-time low$6999.6860 (Dec 17, 2025)
52-week high$7349.6703
52-week low$6999.6860
Median price$7349.6703
Average price$7266.6249
Largest weekly change+5.0% (Feb 11, 2026)
Weeks tracked36
Tracking sinceDec 17, 2025

Price History

1W

+0.1%

1M

+0.1%

3M

-0.4%

6M

-0.4%

1Y

N/A

3Y

N/A

5Y

N/A

All

+4.6%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the guselkumab market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

TREMFYA 100 MG/ML SYRINGE
Brand
57894064001•Janssen Biotech, Inc.
$14728.9053
per ML
TREMFYA 100 MG/ML ONE-PRESS
Brand
57894064011•Janssen Biotech, Inc.
$14745.8421
per ML
SKYRIZI 150 MG/ML PEN
Brand
00074210001•AbbVie Inc.
$22761.4629
per ML
SKYRIZI 150 MG/ML SYRINGE
Brand
00074105001•AbbVie Inc.
$22887.4386
per ML
STELARA 90 MG/ML SYRINGE
Brand
57894006103•Janssen Biotech, Inc.
$29792.7867
per ML
STELARA 45 MG/0.5 ML SYRINGE
Brand
57894006003•Janssen Biotech, Inc.
$29874.4480
per ML

Frequently asked questions

What is the NADAC price of TREMFYA 200 MG/2 ML PEN?

The current National Average Drug Acquisition Cost (NADAC) for TREMFYA 200 MG/2 ML PEN, manufactured by Janssen Biotech, Inc., is $7318.9883 per ML (NDC 57894065102), effective Aug 19, 2026.

How has the price of TREMFYA 200 MG/2 ML PEN changed over time?

Over the history we have for it, the NADAC for TREMFYA 200 MG/2 ML PEN has risen 4.6%. It has been tracked across 36 weekly CMS publications since Dec 17, 2025.

What are the highest and lowest recorded NADAC prices for TREMFYA 200 MG/2 ML PEN?

Since Dec 17, 2025, the NADAC for TREMFYA 200 MG/2 ML PEN has ranged from a low of $6999.6860 (Dec 17, 2025) to a high of $7349.6703 (Jul 15, 2026), with a median of $7349.6703 per ML.

Are there cheaper alternatives to TREMFYA 200 MG/2 ML PEN?

No other NADAC-published product currently shares the active ingredient and strength of TREMFYA 200 MG/2 ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures TREMFYA 200 MG/2 ML PEN?

TREMFYA 200 MG/2 ML PEN (NDC 57894065102) is labeled by Janssen Biotech, Inc., and CMS classifies it as a brand product.